Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
NCT03323476Phase 3Active, not recruiting
- Sponsor
- CHD Vendée
- Start
- Feb 2018
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and end stage renal disease (ESRD) (2 arms), sponsored by CHD Vendée. Primary endpoint: Time between inclusion and the first severe prejudicial event at 24 months. Started Feb 2018; status: active, not recruiting.
02
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT03323476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03323476.